Skip to Content

COVID-19 Treatments

The U.S. Food and Drug Administration (FDA) has authorized the following outpatient treatments:

  • Paxlovid (nirmatrelvir/ritonavir), an oral antiviral, is for individuals 12 years of age and older weighing at least 40 kg. Therapy must begin within five days of symptom onset. Patients on interacting medications may not qualify for therapy. Not recommended for severe renal or liver failure.
  • Remdesivir, an IV antiviral, is for adults and certain pediatric patients. Therapy must begin within seven days of symptom onset. Not recommended for severe renal or liver failure. Three appointments are required. There may be a copayment depending on the insurance provider.   
  • Molnupiravir, an oral antiviral, is for adults only. Therapy must begin within five days of symptom onset. This option is reserved for patients who are not candidates for other therapies.  

Learn more about these treatments at fda.gov.

Who Qualifies?

Some factors may increase your risk of developing severe disease or being hospitalized. Factors include older age, lung problems, heart disease, cancer, diabetes, weakened immune system, kidney or liver disease, pregnancy and obesity.   

Oral antivirals are NOT authorized for use in patients:

  • Requiring hospitalization due to COVID-19
  • For pre-exposure or post-exposure prophylaxis
  • For longer than five days of therapy

How can I access these treatments?

Patients with a test-confirmed COVID-19 diagnosis who are experiencing symptoms may be eligible for outpatient treatment. Please contact your primary care provider to see what treatment options may be available. Stephens Pharmacy at CMH is a Test to Treat location. Testing is available at the drive-thru window. Patients will be asked to wait in their vehicle for results and a prescription if they qualify for oral antivirals. Please call 417-326-2416 for more information.  

CMH Infusion Center

A CMH Infusion Center staff member will contact patients who are approved for therapy to set up an appointment. Patients will receive instructions for arrival and check-in at that time. Patients will be provided with the EUA Fact Sheet before infusion. Patients must stay at the infusion site for one hour of observation following their infusion. 

Call 417-328-4300 to find out if you are a candidate for treating mild to moderate COVID-19.

Back
to Top